Symbols / ICCC Stock $8.36 +4.44% ImmuCell Corporation

Healthcare • Biotechnology • United States • NCM
ICCC (Stock) Chart
O: — H: — L: — C: — V: —
SMA 20: SMA 50: SMA 200:
Stock Fundamentals
Scroll to Statements
Index EQUITY
Sector Healthcare
Industry Biotechnology
CEO
Exch · Country NCM · United States
Market Cap 75.59M
Enterprise Value 84.97M
Income -1.04M
Sales 27.64M
FCF (ttm) 998.36K
Book/sh 2.99
Cash/sh 0.42
Employees 73
Insider 10d
IPO May 05, 1987
Div forward ($/yr)
Div TTM ($/yr)
Dividend Yield
Ex-Div Date
5Y Avg Yield
Yield vs 5Y Avg
Payout 0.00%
P/E
Forward P/E -75.95
PEG
P/S 2.73
P/B 2.79
P/C
EV/EBITDA 16.41
EV/Sales 3.07
Quick Ratio 1.82
Current Ratio 4.26
Debt/Eq 48.77
LT Debt/Eq
EPS (ttm) -0.12
EPS next Y -0.11
EPS Growth
Revenue Growth -1.60%
EPS Gr Q/Q
Rev Gr Q/Q
Earnings (next) 2026-05-14
Earnings (prior) 2021-02-22
ROA 3.49%
ROE -3.81%
ROIC
Gross Margin 41.40%
Oper. Margin 9.73%
Profit Margin -3.76%
Shs Outstand 9.05M
Shs Float 6.02M
Insider Own 32.10%
Instit Own 20.43%
Short Float 0.36%
Short Ratio 1.17
Short Interest 27.13K
52W High 8.46
vs 52W High -1.24%
52W Low 4.52
vs 52W Low 84.85%
Beta 0.31
Impl. Vol.
Rel Volume 1.56
Avg Volume 18.83K
Volume 29.41K
Target (mean)
Tgt Median
Tgt Low
Tgt High
# Analysts
Recom None
Prev Close $8.00
Price $8.36
Change 4.44%
About

ImmuCell Corporation, an animal health company, develops, manufactures, and sells products that enhance the health and productivity of dairy and beef cattle in the United States and internationally. It operates through two segments: Scours and Mastitis. The company offers First Defense, an orally delivered scours preventive product for calves with claims against E. coli, coronavirus, and rotavirus; and Tri-Shield First Defense, a passive antibody product for the treatment of E. coli, coronavirus, and rotavirus. It also provides California Mastitis Test, a quick on-farm diagnostic that is used to detect somatic cell counts in milk, as well as to determine, which quarter of the udder is mastitic; and Dual-Force First Defense, a bivalent gel tube formulation. In addition, the company developing Re-Tain Drug Product, a Nisin-based intramammary treatment of subclinical mastitis in lactating dairy cows. It sells its products through animal health distributors. ImmuCell Corporation was incorporated in 1982 and is headquartered in Portland, Maine.

Valuation Models

Price estimates from analyst targets and simple models.

1. Analyst consensus Mean price target
2. Current target Latest analyst target
3. DCF / Fair value Simplified: (Free Cash Flow ÷ Shares) × 18 (P/FCF multiple). Not a …
Ratings
Current target
$8.36
Low
High
Mean

Latest analyst rating changes

Date Action Analyst Rating Change Price Target
2020-07-13 init Aegis Capital — → Buy $14
Insider Transactions
Filed Date Insider Relationship Transaction Shares Price Value SEC
2026-03-20 BRIGHAM MICHAEL F Director 25,000 $5.84 $146,000
2025-12-04 TE BOEKHORST PAUL FRANCIS OLIVIER Chief Executive Officer 9,738 $4.87 $49,581
2025-12-03 TE BOEKHORST PAUL FRANCIS OLIVIER Chief Executive Officer 9,785 $4.87 $48,588
2025-11-25 TOMSCHE DAVID SCOTT Director 3,266 $4.76 $15,554
2025-06-12 GATHAGAN BRYAN K Director 1,000 $6.32 $6,320
2025-06-11 BASSE GLORIA F Director 3,530 $4.81 $16,979
Financials
Statement View
Amounts in millions (2 decimals, no suffix) • EPS per share (2 decimals) • Trend = period evolution • YoY Growth = previous period %
Line Item Trend 2025-12-31 2024-12-31 2023-12-31 2022-12-31
Total Revenue
27.64
+4.34%
26.49
+51.64%
17.47
-5.90%
18.57
Operating Revenue
27.64
+4.34%
26.49
+51.64%
17.47
-5.90%
18.57
Cost Of Revenue
16.20
-12.68%
18.55
+36.39%
13.60
+24.57%
10.92
Reconciled Cost Of Revenue
16.20
-12.68%
18.55
+36.39%
13.60
+24.57%
10.92
Gross Profit
11.45
+44.13%
7.94
+105.23%
3.87
-49.41%
7.65
Operating Expense
9.80
+2.24%
9.58
-0.38%
9.62
-3.32%
9.95
Research And Development
3.04
-21.97%
3.90
-11.29%
4.39
-2.20%
4.49
Selling General And Administration
6.75
+18.85%
5.68
+8.81%
5.22
-4.24%
5.45
Selling And Marketing Expense
3.55
+2.52%
3.47
+12.24%
3.09
-3.19%
3.19
General And Administrative Expense
3.20
+44.40%
2.22
+3.85%
2.13
-5.72%
2.26
Other Gand A
3.20
+44.40%
2.22
+3.85%
2.13
-5.72%
2.26
Total Expenses
25.99
-7.60%
28.13
+21.16%
23.22
+11.28%
20.87
Operating Income
1.65
+200.56%
-1.64
+71.47%
-5.75
-150.03%
-2.30
Total Operating Income As Reported
1.65
+200.56%
-1.64
+71.47%
-5.75
-150.03%
-2.30
EBITDA
2.14
+100.64%
1.07
+141.03%
-2.60
-842.88%
0.35
Normalized EBITDA
4.49
+314.68%
1.08
+136.59%
-2.96
-962.98%
0.34
Reconciled Depreciation
2.73
+1.58%
2.69
-1.10%
2.72
+9.22%
2.49
EBIT
-0.59
+63.63%
-1.62
+69.52%
-5.32
-148.74%
-2.14
Total Unusual Items
-2.35
-15148.28%
-0.02
-104.31%
0.36
+4768.12%
0.01
Total Unusual Items Excluding Goodwill
-2.35
-15148.28%
-0.02
-104.31%
0.36
+4768.12%
0.01
Special Income Charges
-2.35
-15148.28%
-0.02
-104.31%
0.36
+4768.12%
0.01
Other Special Charges
-0.43
-0.37
Impairment Of Capital Assets
2.67
Net Income
-1.04
+51.78%
-2.16
+62.65%
-5.77
-131.56%
-2.49
Pretax Income
-1.03
+52.09%
-2.15
+62.80%
-5.77
-132.09%
-2.49
Net Non Operating Interest Income Expense
-0.33
+31.84%
-0.49
-29.55%
-0.38
-93.94%
-0.20
Interest Expense Non Operating
0.44
-16.54%
0.53
+16.13%
0.45
+29.97%
0.35
Net Interest Income
-0.33
+31.84%
-0.49
-29.55%
-0.38
-93.94%
-0.20
Interest Expense
0.44
-16.54%
0.53
+16.13%
0.45
+29.97%
0.35
Interest Income Non Operating
0.16
+104.25%
0.08
-19.54%
0.10
-36.92%
0.15
Interest Income
0.16
+104.25%
0.08
-19.54%
0.10
-36.92%
0.15
Other Income Expense
-2.34
-15123.75%
-0.02
-104.31%
0.36
+4231.01%
0.01
Other Non Operating Income Expenses
0.00
0.00
-88.27%
0.00
Tax Provision
0.01
+15.06%
0.01
+117.33%
0.00
-39.69%
0.01
Tax Rate For Calcs
0.00
+0.00%
0.00
+0.00%
0.00
+6674.19%
0.00
Tax Effect Of Unusual Items
-0.49
-15148.28%
-0.00
-104.31%
0.07
+329675.94%
0.00
Net Income Including Noncontrolling Interests
-1.04
+51.78%
-2.16
+62.65%
-5.77
-131.56%
-2.49
Net Income From Continuing Operation Net Minority Interest
-1.04
+51.78%
-2.16
+62.65%
-5.77
-131.56%
-2.49
Net Income From Continuing And Discontinued Operation
-1.04
+51.78%
-2.16
+62.65%
-5.77
-131.56%
-2.49
Net Income Continuous Operations
-1.04
+51.78%
-2.16
+62.65%
-5.77
-131.56%
-2.49
Normalized Income
0.81
+137.96%
-2.14
+64.59%
-6.06
-142.16%
-2.50
Net Income Common Stockholders
-1.04
+51.78%
-2.16
+62.65%
-5.77
-131.56%
-2.49
Diluted EPS
-0.26
+65.33%
-0.75
-134.38%
-0.32
Basic EPS
-0.26
+65.33%
-0.75
-134.38%
-0.32
Basic Average Shares
8.17
+5.41%
7.75
+0.04%
7.75
Diluted Average Shares
8.17
+5.41%
7.75
+0.04%
7.75
Diluted NI Availto Com Stockholders
-1.04
+51.78%
-2.16
+62.65%
-5.77
-131.56%
-2.49
Gain On Sale Of PPE
-0.11
-590.99%
-0.02
-90.04%
-0.01
-210.43%
0.01
Total Other Finance Cost
0.05
+27.38%
0.04
+88.63%
0.02
+195.36%
0.01
Line Item Trend 2025-12-31 2024-12-31 2023-12-31 2022-12-31
Total Assets
42.53
-5.69%
45.10
+2.95%
43.81
-2.35%
44.86
Current Assets
16.94
+12.64%
15.04
+31.15%
11.47
-18.04%
13.99
Cash Cash Equivalents And Short Term Investments
3.81
+1.29%
3.76
+283.99%
0.98
-83.10%
5.79
Cash And Cash Equivalents
3.81
+1.29%
3.76
+283.99%
0.98
-83.10%
5.79
Other Short Term Investments
Receivables
3.45
-9.48%
3.81
+71.30%
2.23
+23.56%
1.80
Accounts Receivable
3.42
-9.34%
3.77
+72.56%
2.19
+24.27%
1.76
Other Receivables
0.03
-23.12%
0.04
+2.07%
0.04
-5.80%
0.04
Inventory
9.27
+30.29%
7.11
-8.95%
7.81
+29.37%
6.04
Raw Materials
1.65
+21.72%
1.36
-14.92%
1.59
-34.13%
2.42
Work In Process
5.75
+0.04%
5.75
-1.18%
5.82
+67.65%
3.47
Finished Goods
1.87
+19498.13%
0.01
-97.63%
0.40
+168.67%
0.15
Prepaid Assets
0.42
+16.74%
0.36
-20.69%
0.45
+24.81%
0.36
Total Non Current Assets
25.59
-14.87%
30.06
-7.05%
32.34
+4.77%
30.87
Net PPE
25.45
-14.90%
29.91
-6.96%
32.15
+4.93%
30.64
Gross PPE
44.29
-13.07%
50.95
+0.63%
50.63
+8.86%
46.51
Accumulated Depreciation
-18.84
+10.47%
-21.04
-13.84%
-18.48
-16.43%
-15.88
Properties
0.00
0.00
0.00
0.00
Land And Improvements
0.52
+0.00%
0.52
+0.00%
0.52
+0.00%
0.52
Buildings And Improvements
20.90
+0.06%
20.89
+0.50%
20.78
+3.66%
20.05
Machinery Furniture Equipment
0.70
-33.45%
1.06
+1.91%
1.04
+15.11%
0.90
Construction In Progress
0.53
-80.17%
2.69
-2.68%
2.77
-24.53%
3.67
Other Properties
21.64
-16.13%
25.79
+1.06%
25.52
+19.40%
21.38
Goodwill And Other Intangible Assets
0.10
-16.66%
0.11
-14.28%
0.13
-12.50%
0.15
Goodwill
0.10
+0.00%
0.10
+0.00%
0.10
+0.00%
0.10
Other Intangible Assets
0.02
-50.00%
0.04
-33.33%
0.06
Other Non Current Assets
0.04
+12.94%
0.03
-42.12%
0.06
-24.76%
0.08
Total Liabilities Net Minority Interest
15.48
-11.97%
17.58
-6.55%
18.82
+29.93%
14.48
Current Liabilities
3.98
-9.84%
4.41
+5.12%
4.20
+36.63%
3.07
Payables And Accrued Expenses
2.28
-8.05%
2.48
+16.86%
2.12
+6.17%
2.00
Payables
0.80
-15.43%
0.95
+6.59%
0.89
+12.06%
0.79
Accounts Payable
0.80
-15.62%
0.94
+6.30%
0.89
+12.37%
0.79
Current Accrued Expenses
1.48
-3.49%
1.53
+24.28%
1.23
+2.29%
1.21
Total Tax Payable
0.01
+15.12%
0.01
+90.59%
0.00
-37.61%
0.00
Income Tax Payable
0.01
+15.12%
0.01
+90.59%
0.00
-37.61%
0.00
Current Debt And Capital Lease Obligation
1.70
-12.13%
1.93
-6.92%
2.07
+93.53%
1.07
Current Debt
1.61
+7.52%
1.50
+4.82%
1.43
+37.46%
1.04
Other Current Borrowings
1.61
+7.52%
1.50
+4.82%
1.43
+37.46%
1.04
Current Capital Lease Obligation
0.09
-80.21%
0.43
-32.94%
0.64
+1928.32%
0.03
Total Non Current Liabilities Net Minority Interest
11.50
-12.69%
13.17
-9.90%
14.62
+28.13%
11.41
Long Term Debt And Capital Lease Obligation
11.50
-12.69%
13.17
-9.90%
14.62
+28.13%
11.41
Long Term Debt
7.49
-17.17%
9.04
-14.23%
10.54
+14.68%
9.19
Long Term Capital Lease Obligation
4.01
-2.89%
4.13
+1.28%
4.08
+83.87%
2.22
Stockholders Equity
27.06
-1.68%
27.52
+10.10%
24.99
-17.73%
30.38
Common Stock Equity
27.06
-1.68%
27.52
+10.10%
24.99
-17.73%
30.38
Capital Stock
0.91
+0.70%
0.90
+15.72%
0.78
+0.00%
0.78
Common Stock
0.91
+0.70%
0.90
+15.72%
0.78
+0.00%
0.78
Share Issued
9.11
+0.70%
9.04
+15.72%
7.81
+0.00%
7.81
Ordinary Shares Number
9.05
+0.74%
8.98
+15.85%
7.75
+0.05%
7.75
Treasury Shares Number
0.06
-5.58%
0.06
+0.00%
0.06
-5.94%
0.07
Additional Paid In Capital
41.48
+1.38%
40.92
+12.54%
36.36
+1.05%
35.98
Retained Earnings
-15.20
-7.34%
-14.16
-17.96%
-12.01
-92.65%
-6.23
Treasury Stock
0.13
-5.58%
0.14
+0.00%
0.14
-5.94%
0.15
Total Equity Gross Minority Interest
27.06
-1.68%
27.52
+10.10%
24.99
-17.73%
30.38
Total Capitalization
34.54
-5.51%
36.56
+2.89%
35.53
-10.20%
39.57
Working Capital
12.97
+21.98%
10.63
+46.18%
7.27
-33.42%
10.92
Invested Capital
36.15
-5.00%
38.06
+2.96%
36.96
-8.98%
40.61
Total Debt
13.19
-12.62%
15.10
-9.53%
16.69
+33.74%
12.48
Net Debt
5.29
-21.95%
6.78
-38.31%
10.99
+147.59%
4.44
Capital Lease Obligations
4.10
-10.21%
4.56
-3.39%
4.72
+109.92%
2.25
Net Tangible Assets
26.96
-1.62%
27.40
+10.23%
24.86
-17.76%
30.23
Tangible Book Value
26.96
-1.62%
27.40
+10.23%
24.86
-17.76%
30.23
Line Item Trend 2025-12-31 2024-12-31 2023-12-31 2022-12-31
Operating Cash Flow
2.48
+591.61%
0.36
+107.66%
-4.67
-202.76%
-1.54
Cash Flow From Continuing Operating Activities
2.48
+591.61%
0.36
+107.66%
-4.67
-202.76%
-1.54
Net Income From Continuing Operations
-1.04
+51.78%
-2.16
+62.65%
-5.77
-131.56%
-2.49
Depreciation Amortization Depletion
2.73
+1.58%
2.69
-1.10%
2.72
+9.22%
2.49
Depreciation
2.71
+1.59%
2.67
-1.11%
2.70
+9.29%
2.47
Amortization Cash Flow
0.02
+0.00%
0.02
+0.00%
0.02
+0.00%
0.02
Depreciation And Amortization
2.73
+1.58%
2.69
-1.10%
2.72
+9.22%
2.49
Amortization Of Intangibles
0.02
+0.00%
0.02
+0.00%
0.02
+0.00%
0.02
Other Non Cash Items
2.44
+2375.60%
-0.11
-190.48%
0.12
+227.51%
0.04
Stock Based Compensation
0.30
-9.12%
0.33
-11.74%
0.37
+38.54%
0.27
Deferred Tax
Deferred Income Tax
Operating Gains Losses
0.11
+590.99%
0.02
+90.04%
0.01
+210.43%
-0.01
Gain Loss On Sale Of PPE
0.11
+590.99%
0.02
+90.04%
0.01
+210.43%
-0.01
Change In Working Capital
-2.05
-405.05%
-0.41
+80.75%
-2.11
-15.24%
-1.83
Change In Receivables
0.35
+122.21%
-1.59
-271.56%
-0.43
-145.61%
0.94
Changes In Account Receivables
0.35
+122.21%
-1.59
-271.56%
-0.43
-145.61%
0.94
Change In Inventory
-2.15
-408.17%
0.70
+139.43%
-1.77
+39.86%
-2.95
Change In Prepaid Assets
-0.05
-154.67%
0.09
+206.03%
-0.09
+20.77%
-0.11
Change In Payables And Accrued Expense
-0.20
-153.85%
0.36
+130.97%
0.16
-54.04%
0.34
Change In Other Current Assets
-0.00
-117.78%
0.02
+28.01%
0.02
+137.56%
-0.05
Investing Cash Flow
-1.21
-163.28%
-0.46
+75.60%
-1.89
+52.32%
-3.96
Cash Flow From Continuing Investing Activities
-1.21
-163.28%
-0.46
+75.60%
-1.89
+52.32%
-3.96
Net PPE Purchase And Sale
-1.21
-163.28%
-0.46
+75.60%
-1.89
+52.32%
-3.96
Purchase Of PPE
-1.25
-168.49%
-0.47
+75.39%
-1.89
+52.39%
-3.98
Sale Of PPE
0.04
+702.93%
0.00
+81.89%
0.00
-77.51%
0.01
Capital Expenditure
-1.25
-168.49%
-0.47
+75.39%
-1.89
+52.39%
-3.98
Net Investment Purchase And Sale
0.00
Purchase Of Investment
Sale Of Investment
0.00
Net Other Investing Changes
Financing Cash Flow
-1.21
-142.06%
2.88
+64.60%
1.75
+57.19%
1.11
Cash Flow From Continuing Financing Activities
-1.21
-142.06%
2.88
+64.60%
1.75
+57.19%
1.11
Net Issuance Payments Of Debt
-1.48
-0.74%
-1.47
-180.93%
1.81
+64.50%
1.10
Issuance Of Debt
0.80
0.00
-100.00%
5.00
+150.00%
2.00
Repayment Of Debt
-2.28
-55.31%
-1.47
+53.91%
-3.19
-255.11%
-0.90
Long Term Debt Issuance
0.80
0.00
-100.00%
5.00
+150.00%
2.00
Long Term Debt Payments
-2.28
-55.31%
-1.47
+53.91%
-3.19
-255.11%
-0.90
Net Long Term Debt Issuance
-1.48
-0.74%
-1.47
-180.93%
1.81
+64.50%
1.10
Short Term Debt Issuance
2.00
0.00
Short Term Debt Payments
-2.00
0.00
Net Short Term Debt Issuance
0.00
0.00
Net Common Stock Issuance
0.35
-92.48%
4.65
0.00
0.00
Proceeds From Stock Option Exercised
0.00
0.00
-100.00%
0.02
-38.83%
0.03
Net Other Financing Charges
-0.08
+72.21%
-0.30
-264.12%
-0.08
-322.31%
-0.02
Changes In Cash
0.05
-98.25%
2.78
+157.75%
-4.81
-9.53%
-4.39
Beginning Cash Position
3.76
+283.99%
0.98
-83.10%
5.79
-43.14%
10.19
End Cash Position
3.81
+1.29%
3.76
+283.99%
0.98
-83.10%
5.79
Free Cash Flow
1.22
+1236.00%
-0.11
+98.36%
-6.57
-18.98%
-5.52
Interest Paid Supplemental Data
0.44
-16.24%
0.53
+18.87%
0.44
+31.44%
0.34
Income Tax Paid Supplemental Data
0.01
+46.59%
0.01
+12.79%
0.01
+31.34%
0.00
Common Stock Issuance
0.35
-92.48%
4.65
0.00
0.00
Issuance Of Capital Stock
0.35
-92.48%
4.65
0.00
0.00
SEC Filings

Recent 10-K, 10-Q, 8-K, and Form 4 (insider) filings.

Trades
Date User Broker Pattern Type Position Size Entry Price Trade P&L Status
Posts
Published Title Author Category